Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Issues Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Issues Volumes Webinars Videos

Volume

P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport

Concomitant medications and circulating tumor cells: friends or foes?

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities

Nano-TRAIL: a promising path to cancer therapy

Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Targeting regulated cell death pathways in acute myeloid leukemia

Anti-BCMA novel therapies for multiple myeloma

Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance

Targeting MYC-driven lymphoma: lessons learned and future directions

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the “Cancer Stem Cells and Drug Resistance”

miR-16-5p enhances sensitivity to RG7388 through targeting <i>PPM1D</i> expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Importance of <i>ROS1</i> gene fusions in non-small cell lung cancer

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Interaction of pregnane X receptor with hypoxia-inducible factor-1 regulates chemoresistance of prostate cancer cells

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers

The multifaceted role of extracellular vesicles in prostate cancer-a review

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

New mechanisms of multidrug resistance: an introduction to the <i>Cancer Drug Resistance</i> special collection

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Emerging resistance <i>vs.</i> losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

Drug resistance in glioblastoma: from chemo- to immunotherapy

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

Unlocking antitumor immunity with adenosine receptor blockers

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

Emerging roles of 3D-culture systems in tackling tumor drug resistance

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

Autophagy-related mechanisms for treatment of multiple myeloma

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
partners@oaepublish.com Company Contact Us
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2024 OAE Publishing Inc., except certain content provided by third parties